Scientists at Yale University have developed a very sensitive and specific test for the early detection of ovarian cancer. Results of the second phase of clinical trials have shown that it can be used to diagnose cancer, are up to 99% according to the journal Clinical Cancer Research. The test is based on the determination of the concentration of six protein biomarkers in a small amount of blood serum based. Among them - the proteins that are produced in the body in response to the tumor, or produced by the tumor itself, said study leader Gil Mor (Gil Mor). According to him the previous tests were based only on the determination of tumor proteins, and their accuracy is not more than 15-20%. In the second phase of the clinical trial involved 500 people, 150 of them were suffering with ovarian cancer. The test results were evaluated not only by researchers, but also by independent experts from the U.S. National Cancer Institute. A multicenter clinical trial of 2,000 patients - Currently, Moore and his colleagues have already started Phase III trials test. "We hope that this test will be prescribed one of the most common medical tests for the study of women" - Moore said. Ovarian cancer is a leading cause of death from cancer in women. The disease is called the "silent killer": The cancer has long flowing asymptomatic and often detected in later, incurable stage.
No comments:
Post a Comment